January 2026 Penny Stock Spotlight: Three Promising Picks

Simply Wall St.01-12

The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602543848?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-12 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602543848","market":"nz","top_or_hot":-1,"title":"January 2026 Penny Stock Spotlight: Three Promising Picks","media":"Simply Wall St.","content":"<div>\n<p>The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/january-2026-penny-stock-spotlight-three-promising-picks\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>January 2026 Penny Stock Spotlight: Three Promising Picks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanuary 2026 Penny Stock Spotlight: Three Promising Picks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 19:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/january-2026-penny-stock-spotlight-three-promising-picks><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/january-2026-penny-stock-spotlight-three-promising-picks\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/january-2026-penny-stock-spotlight-three-promising-picks","article_id":"2602543848","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/january-2026-penny-stock-spotlight-three-promising-picks","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602543848","pubTimestamp":1768215905,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance sets an intriguing backdrop for exploring investment opportunities in penny stocks, which often represent smaller or newer companies that can offer significant growth potential. Despite their somewhat outdated name, penny stocks remain relevant for investors seeking affordability combined with the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4094":"服装零售","MAPS":"WM Technology, Inc.","BK4509":"腾讯概念","LCUT":"生活时光品牌家具","BK4539":"次新股","BK4023":"应用软件","BK4209":"餐馆","LX":"乐信","LU0049112450.USD":"FIDELITY PACIFIC \"A\" INC","DDL":"叮咚买菜","BK4113":"食品零售","ALLO":"Allogene Therapeutics Inc.","BK4531":"中概回港概念","BK4526":"热门中概股","LU1235295612.USD":"FIDELITY PACIFIC \"A\" (USDHDG) INC","BK4139":"生物科技","CINT":"CI&T Inc.","BK4173":"保险经纪商","BK4122":"互联网与直销零售","SFIX":"Stitch Fix Inc.","BK4180":"家用器具与特殊消费品","BK4505":"高瓴资本持仓","TUYA":"涂鸦智能","BK4535":"淡马锡持仓","CRCT":"Cricut, Inc.","LU1046422090.SGD":"Fidelity Pacific A-SGD","WDH":"水滴","BK4166":"消费信贷","BK4191":"家用电器","BK4579":"人工智能","BABB":"BAB, Inc.","BK4134":"信息科技咨询与其它服务","CHRS":"Coherus Biosciences"},"translate_title":"2026年1月细价股聚焦：三个有前途的精选","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1,"ALLO":1,"LCUT":1,"SFIX":1,"BABB":1,"CINT":1,"CRCT":1,"TUYA":1,"MAPS":1,"WDH":1,"DDL":1,"LX":1},"content_text":"The U.S. stock market has started 2026 with a bang, as major indexes like the Dow Jones Industrial Average and S&P 500 have hit record highs following a week of strong gains. This robust performance sets an intriguing backdrop for exploring investment opportunities in penny stocks, which often represent smaller or newer companies that can offer significant growth potential. Despite their somewhat outdated name, penny stocks remain relevant for investors seeking affordability combined with the possibility of outsized returns when backed by solid financial health.AdvertisementTop 10 Penny Stocks In The United StatesNameShare PriceMarket CapRewards & RisksDingdong (Cayman) (DDL)$2.97$636.49M✅ 3 ⚠️ 1 View Analysis >Waterdrop (WDH)$1.845$669.08M✅ 4 ⚠️ 0 View Analysis >WM Technology (MAPS)$0.8636$147.69M✅ 4 ⚠️ 1 View Analysis >LexinFintech Holdings (LX)$3.01$506.47M✅ 4 ⚠️ 2 View Analysis >Tuya (TUYA)$2.20$1.33B✅ 4 ⚠️ 1 View Analysis >CI&T (CINT)$4.82$625.72M✅ 5 ⚠️ 0 View Analysis >Golden Growers Cooperative (GGRO.U)$5.00$77.45M✅ 1 ⚠️ 5 View Analysis >Cricut (CRCT)$4.84$1.02B✅ 2 ⚠️ 2 View Analysis >BAB (BABB)$0.92$6.68M✅ 2 ⚠️ 3 View Analysis >Lifetime Brands (LCUT)$4.07$92.21M✅ 3 ⚠️ 2 View Analysis >Click here to see the full list of 337 stocks from our  US Penny Stocks screener.We're going to check out a few of the best picks from our screener tool.Coherus Oncology (CHRS)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: Coherus Oncology, Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing immunotherapies for cancer treatment in the United States, with a market cap of $204.27 million.Operations: The company generates revenue of $277.73 million from the development and commercialization of biosimilar products.Market Cap: $204.27MCoherus Oncology, Inc. is a biopharmaceutical company with a market cap of US$204.27 million and revenues of US$277.73 million from biosimilar products, indicating it is not pre-revenue. The company recently became profitable and has shown financial improvement by reducing its debt-to-equity ratio significantly over the past five years while maintaining outstanding return on equity at 69.5%. Despite high volatility in share price, Coherus trades at a favorable price-to-earnings ratio of 3.3x compared to the broader market average of 19.3x, suggesting potential value for investors interested in penny stocks with robust financial metrics and ongoing clinical developments like tagmokitug in immunotherapy trials.Dive into the specifics of Coherus Oncology here with our thorough balance sheet health report.Gain insights into Coherus Oncology's outlook and expected performance with our report on the company's earnings estimates.CHRS Debt to Equity History and Analysis as at Jan 2026Allogene Therapeutics (ALLO)Simply Wall St Financial Health Rating: ★★★★★★Overview: Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $384.29 million.Operations: Allogene Therapeutics, Inc. does not report any revenue segments as it is a clinical-stage company focused on developing allogeneic T cell therapies.Market Cap: $384.29MAllogene Therapeutics, Inc., with a market cap of US$384.29 million, is a pre-revenue clinical-stage company focused on allogeneic T cell therapies. Despite being unprofitable and having a negative return on equity, Allogene benefits from experienced management and board members. The company is debt-free and has short-term assets of US$260.7 million exceeding liabilities, ensuring financial stability for over a year based on current cash flow trends. Recent developments highlight 2026 as pivotal for its CAR T platform with multiple clinical readouts anticipated to validate its off-the-shelf approach in oncology and autoimmune diseases, potentially enhancing patient access and treatment scalability.Click here to discover the nuances of Allogene Therapeutics with our detailed analytical financial health report.Learn about Allogene Therapeutics' future growth trajectory here.ALLO Financial Position Analysis as at Jan 2026Stitch Fix (SFIX)Simply Wall St Financial Health Rating: ★★★★★★Overview: Stitch Fix, Inc. operates in the United States, offering clothing and accessories, with a market cap of approximately $668.31 million.Operations: Stitch Fix generates revenue primarily through its online retail segment, which accounted for $1.29 billion.Market Cap: $668.31MStitch Fix, Inc., with a market cap of US$668.31 million, operates in the online retail sector and reported first-quarter sales of US$342.13 million. Despite being unprofitable, the company has reduced its losses over five years and maintains a stable cash runway exceeding three years due to positive free cash flow. Stitch Fix is debt-free with short-term assets of US$435.4 million surpassing both short- and long-term liabilities, reflecting financial stability without recent shareholder dilution. The management team is experienced, although the company faces challenges with negative return on equity and no immediate profitability forecasted within three years.Jump into the full analysis health report here for a deeper understanding of Stitch Fix.Review our growth performance report to gain insights into Stitch Fix's future.SFIX Debt to Equity History and Analysis as at Jan 2026Seize The OpportunityUnlock our comprehensive list of 337  US Penny Stocks by clicking here.Interested In Other Possibilities? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602543848","isCrawlerRequest":true}